Clinical trial recruitment platform Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study enrolment by converting patient matches into actual subjects.
The company said that 86% of trials experience delays due to recruitment issues, resulting in the pharma industry incurring significant losses daily, while patients endure lengthy waits for potentially life-saving treatments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As the first fully integrated AI platform designed to address these delays, Trially employs Health Insurance Portability and Accountability Act (HIPAA)-compliant large language model (LLM) agents that can analyse medical data that is not structured, for matching, connecting, and enrolling subjects in suitable trials instantly.
This approach streamlines a process that traditionally required multiple hours of manual chart reviews and extensive cold calling, turning it into an opportunity for instant enrolment.
Margo consolidates several key services, including Trially Match, which utilises the platform’s capability to read medical data and match subjects instantly with appropriate clinical studies.
Powered by Margo’s agentic AI outreach, Trially Connect pre-screens subject matches to transform qualified participants into enrolments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdditionally, Trially Intelligence acts as a pipeline radar, providing proactive alerts about studies that match a subject population, accompanied by instant feasibility analytics.
The funding round was spearheaded by Flyover Capital and saw participation from investors, including Atria, Alpaca, Blu Ventures, Redbud, Looking Glass Capital, Gaingels, and The Council.
With the infusion of new capital, Trially is set to accelerate the adoption of its platform across research sites, contract research organisations (CROs), physician networks, and pharma sponsors.
Trially CEO and co-founder Kyle McAllister said: “Recruitment has always been the bottleneck in clinical research. With Margo, we’re not just matching patients, we’re engaging and enrolling them.
“That’s what sets Trially apart: we can identify patients with ~95% screening accuracy and then agentic AI can engage them at the exact moment it matters most.”
